WEBULL
WebtradeDownload

US High Growth Tech Stocks to Watch for Potential Portfolio Boost

Simply Wall St · 1d ago

Over the last 7 days, the United States market has experienced a 1.6% drop, yet it remains up by 12% over the past year with earnings anticipated to grow by 17% annually in the coming years. In this context, identifying high growth tech stocks that can potentially enhance a portfolio involves looking for companies with strong innovation and adaptability in an evolving market landscape.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating
Fabrinet 21.15% 21.45% ★★★★★★
Coherent 30.61% 44.10% ★★★★★★
TG Therapeutics 21.58% 21.53% ★★★★★★
Ciena 22.45% 36.25% ★★★★★★
Lumentum Holdings 43.00% 97.59% ★★★★★★
Madrigal Pharmaceuticals 27.67% 64.26% ★★★★★★
Shopify 20.17% 21.03% ★★★★★★
Travere Therapeutics 23.99% 53.11% ★★★★★★
Precigen 37.10% 54.04% ★★★★★★
Snowflake 21.06% 57.42% ★★★★★★

Click here to see the full list of 26 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Ardelyx (ARDX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs both in the United States and internationally, with a market cap of approximately $777.47 million.

Operations: Ardelyx generates revenue primarily from the development and commercialization of biopharmaceutical products, amounting to $450.89 million. The company focuses on addressing unmet medical needs in both domestic and international markets.

Ardelyx's recent advancements and challenges highlight its dynamic role in the high-growth tech sector, particularly within biopharmaceuticals. The company recently showcased significant clinical outcomes at the ACG 2026 meeting, with IBSRELA® reducing healthcare visits for IBS-C patients—a testament to its potential market impact. However, Ardelyx faces hurdles such as increased payer scrutiny which led to a revised downward revenue forecast for IBSRELA and withdrawal of long-term guidance for XPHOZAH, impacting stock value notably in August 2026. Despite these setbacks, Ardelyx maintains a robust R&D focus with $36 million earmarked for future developments, underscoring its commitment to innovation despite current profitability challenges.

ARDX Revenue and Expenses Breakdown as at Oct 2026
ARDX Revenue and Expenses Breakdown as at Oct 2026

Travere Therapeutics (TVTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.88 billion.

Operations: The company generates revenue primarily from the development and commercialization of innovative therapies, amounting to $591.33 million.

With a 24% annual revenue growth, Travere Therapeutics outpaces the US market average of 13.7%. The company's R&D investment reflects its commitment to innovation, crucial for maintaining its competitive edge in the biopharmaceutical sector. Recent data from FILSPARI® trials at ASN Kidney Week 2026 demonstrated significant clinical benefits in kidney disease treatments, potentially positioning it as a first-line therapy. However, leadership changes with CEO Eric Dube stepping down could signal strategic shifts or continuity challenges ahead.

TVTX Earnings and Revenue Growth as at Oct 2026
TVTX Earnings and Revenue Growth as at Oct 2026

Madrigal Pharmaceuticals (MDGL)

Simply Wall St Growth Rating: ★★★★★★

Overview: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) in the United States, with a market cap of $10.45 billion.

Operations: Madrigal focuses on delivering therapeutics for MASH, generating revenue of $1.28 billion from this segment.

Madrigal Pharmaceuticals is navigating a transformative phase, underscored by its aggressive R&D strategy which aligns with its 27.7% annual revenue growth, outstripping the US market average of 13.6%. The company's commitment to innovation is evident in its recent MAESTRO-NASH trial results for Rezdiffra®, showcasing significant therapeutic benefits across various genetic risk profiles, reinforcing its potential in liver disease treatment despite a current unprofitable status. Additionally, the strategic expansion of their headquarters and the inclusion of high-profile executives like John C. Reed to the board highlight Madrigal's readiness to scale operations and deepen research capabilities. These developments suggest a robust trajectory towards profitability, with earnings expected to surge by 64.3% annually.

MDGL Revenue and Expenses Breakdown as at Oct 2026
MDGL Revenue and Expenses Breakdown as at Oct 2026

Taking Advantage

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.